Trials of antidepressants for relapse prevention are confounded by withdrawal effects caused by the drugs.
Neuropsychological assessments reveal the cognitive, occupational, and social impact of polypharmacy in psychiatry.
A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.
New study finds that Medicaid enrolled youth were 14 times more likely to be on an antidepressant in 2014 than in 1987.
Researchers at Johns Hopkins test paroxetine on developing brain cells and discover numerous neurotoxic effects.
New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.
Recent research implicates benzodiazepines as being involved in a high rate of emergency department visits in the US.
Researchers confirm that the suicide warning for antidepressants is justified by the evidence and that claims that the warning is harmful lack support.
A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.
A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.
Current suicide assessment practices of the VA are reductive and do not allow for the individual’s narrative to be heard.
Researcher criticizes the many ways opposing viewpoints and dissenting voices are squashed in the field of medicine.
Researchers suggest that the pharmaceutical industry had a vested interest in using the term “discontinuation” in order to hide the severity of physical dependence and withdrawal reactions many people experience from antidepressants.
A new study finds that clinicians’ disregard for mental health patients’ insight into their own condition may be detrimental to treatment.
In a new study, researchers found no evidence of antidepressant group variance, which means that there's no particular group of patients who improve more than others on the drug.
A new analysis, published in Lancet Neurology, demonstrates how Biogen is spinning results from two failed trials for a new Alzheimer's drug.
An anthropological look at the Global Mental Health (GMH) movement suggests several ethical problems and contradictions in its mission.
Ayahuasca found to be effective in treating moderate to severe depression in low-income population.
An issue of Lancet Psychiatry is devoted to clarifying the lack of efficacy for Zoloft (sertraline).
New research contends that ketamine can reduce problematic alcohol use but does the data support the claims?
Experts across the globe point to the harms of drug companies’ influence on research, practice, and education in healthcare noting that it compromises patient care.
Current standards for clinical trials rely on statistical methods that allow for ineffective treatments to gain approval.
A new special issue brings together articles exploring the harmful effects of simultaneous multiple medication use.
A new study reports that the supplement EPA improved ADHD symptoms but a closer look calls these results into question.
Researchers compared the efficacy of antidepressants using different rating scales and found them to be no different—just slightly better than placebo, and not meeting the criteria for clinical significance.